Orchid Pharma’s 8.77% margin ranks second-lowest among 48 healthcare peers
Zero tax and Rs 13.51 cr of other income supported profit, while management outlined long-term sterile-launch and Cefiderocol capacity plans.
Filed 14 Aug 2026, 18:31 IST · after market close · Orchid Pharma Ltd (ORCHPHARMA)
Key takeaways
- Orchid Pharma’s standalone operating margin of 8.77% was 14.61 percentage points below the 23.38% median for 48 reported healthcare peers.
- A zero tax charge lifted net profit to Rs 32.66 cr, while other income of Rs 13.51 cr was a material contributor to profit before tax.
- Management said its expansion programme includes Rs 200 cr for Cefiderocol access capacity and Rs 50 cr for sterile-product FDF capability and filings.
Price around the results
Standalone profit quality was aided by zero tax and other income
The standalone filing reported profit before tax of Rs 32.66 cr and no tax charge, leaving net profit at the same Rs 32.66 cr. Other income of Rs 13.51 cr was a material contributor to pre-tax profit, so reported earnings were not driven solely by operations. Interest was Rs 1.95 cr and depreciation was Rs 11.18 cr.
The Rs 336.04 cr expense base kept operating margin near the peer-set floor
Expenses of Rs 336.04 cr against revenue of Rs 368.33 cr left operating profit at Rs 32.29 cr and operating margin at 8.77%. Orchid’s margin was 14.61 percentage points below the 23.38% healthcare-sector median, ranking second-lowest among the 48 peers that had reported.
Management outlined a multi-year sterile and Cefiderocol build-out
Management said it is targeting 5-6 sterile US launches by 2030, supported by rolling ANDA filings from FY27 to FY30. The company said the Cefiderocol access project carries committed investment of Rs 200 cr and is designed for 1 million vials of capacity. Management also said Orchid plans to invest Rs 50 cr in FDF capability and filings, while the presentation flags import dependence from a missing control point in the cephalosporin value chain.
The filing came after market close
Orchid filed these standalone results after market close on 14 Aug 2026. There is therefore no same-session stock reaction to interpret for this quarter.
Q4FY26 at a glance
Standalone figures as filed with NSE — cross-checked against an independent source.
| Line item | Q4FY26 |
|---|---|
| Revenue | ₹368 cr |
| Other income | ₹14 cr |
| Expenses | ₹336 cr |
| Operating profit | ₹32 cr |
| Operating margin (%) | 8.77% |
| Interest | ₹2 cr |
| Depreciation | ₹11 cr |
| Profit before tax | ₹33 cr |
| Tax | ₹0 cr |
| Net profit | ₹33 cr |
| EPS (₹) | ₹5.45 |
Operating margin of 8.77% compares with a Healthcare sector median of 23.38% across 48 peers that have reported Q4FY26.
What management said
From the company’s own investor presentation. Each point is checked against the source document before it appears here.
Guidance & outlook
- The company targets 5-6 sterile US launches by 2030, with rolling ANDA filings from FY27 to FY30.
Expansion
- The Cefiderocol access project has committed investment of ₹200 crore and will build 1 million vial capacity.
- Orchid plans to invest ₹50 crore in FDF capability and filings for sterile US launches and rolling ANDA filings.
New initiatives
- Orchid is building peptide synthesis capability and pursuing long-term exploratory biotech fermentation research.
- Orchid is pursuing access pricing to make Cefiderocol available to markets priced out at global rates.
Problems & risks
- Orchid identifies import dependence caused by a missing control point in its cephalosporin value chain.
What to watch
- Whether operating margin moves up from 8.77% in the next reported quarter.
- Progress on management’s committed Rs 200 cr Cefiderocol access project and its planned 1 million-vial capacity.
- Whether management’s stated timetable for 5-6 sterile US launches by 2030 and rolling ANDA filings from FY27 to FY30 remains unchanged.